Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Phase 11 is Completed with outstanding results

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Aug 15, 2021 8:24pm

185 Views

Post# 33707981

RE:RE:RE:Phase 11 is Completed with outstanding results

Wrong. It’s not worse. Like we said a hundred times, the trial was stopped because of a predetermined threshold that was crossed. That does not mean it’s worse for a longer period of time than any other Nsaid.

StockingUp21 wrote:
Recent trial is worse for longer period. Shorter period is fine but this is not what goal is.

LFT's no worse than any other NSAID, but demonstrates unequivocal GI safety superiority of ATB-346 over naproxen, one of the most prescribed NSAIDs in the US.